PD-L1

Oct 18, 2017

BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration

Oct 09, 2017

ARMO BioSciences Appoints Immuno-Oncology Industry Veteran Joseph Leveque, M.D., as Chief Medical Officer

Sep 28, 2017

Roche gains CE label expansion for PD-L1 testing in lung and bladder cancers in markets where TECENTRIQ is approved

Sep 24, 2017

Immune response prognostic for prostate cancer survival, recurrence and response to radiation therapy

Jul 24, 2017

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

Jun 20, 2017

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

Jun 05, 2017

Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models